Apogee Therapeutics (APGE) Treasury Shares (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Treasury Shares data on file, last reported at $358634.0 in Q1 2026.

• Quarterly Treasury Shares rose 46.24% year-over-year to $358634.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $358634.0 (up 46.24% YoY) and the FY2025 annual result came in at $637594.0, down 54.97% from the prior year.
• Treasury Shares retreated to $358634.0 in Q1 2026 per APGE's latest filing, from $637594.0 in the prior quarter.
• Across five years, Treasury Shares topped out at $8.0 million in Q4 2022 and bottomed at $126101.0 in Q2 2024.
• The 5-year median for Treasury Shares is $1.2 million (2024), against an average of $1.7 million.
• Peak annual rise in Treasury Shares reached 714.35% in 2025, while the deepest fall reached 88.26% in 2025.
• Tracing APGE's Treasury Shares over 5 years: stood at $8.0 million in 2022, then tumbled by 71.12% to $2.3 million in 2023, then tumbled by 38.89% to $1.4 million in 2024, then slumped by 54.97% to $637594.0 in 2025, then slumped by 43.75% to $358634.0 in 2026.
• Per Business Quant, the three latest APGE Treasury Shares figures stand at $358634.0 (Q1 2026), $637594.0 (Q4 2025), and $196132.0 (Q3 2025).

Peer Comparison